Over 70 Chinese new drug research and development companies completed financing in the first quarter. These therapies are attracting attention

Source: Guanlan Pharmaceutical

Public information shows that in the first quarter of 2021, China's new drug R&D field (excluding in vitro diagnostics and testing, CRO, etc.

More than one-third of early financing, innovative therapies such as PROTAC molecules lead the way

Among the 72 financing cases we counted, there were 27 cases of early financing (round A++ and before), accounting for more than one-third, involving 26 companies.

Combing the R&D pipelines of these companies, we found that the research of these cutting-edge companies covers many popular research directions at the moment, including gene therapy, a new generation of antibody-conjugated drugs (ADC), PROTAC (protein targeted degradation chimera) molecules, and nanobodies.

It is also worth mentioning that the two companies that completed the A++ round of financing-Qihan Biological and Fubei Biological.

30 cases of financing above the B round, tumor immunotherapy, etc.

At the same time, other companies are developing other new therapies with different mechanisms of action to treat various diseases.

A number of companies received strategic investment, Tianyan Pharmaceutical, Genxi Bio, etc.

In addition, Nuocheng Jianhua, Luye Pharmaceutical, and Qinhao Pharmaceutical have respectively completed strategic investments of different amounts.

Congratulations to these Chinese biopharmaceutical companies at different stages of development for obtaining financial support in the first quarter.

Attached table:

Partial financing in China's new drug R&D field in the first quarter of 2021 (incomplete statistics)

Note: This table is compiled based on public information, and is incomplete statistics.